Synergistic Interactions of Antibodies in Rate of Virus Neutralization  by Paolo Sanna, Pietro et al.
N
T
p
Virology 270, 386–396 (2000)
doi:10.1006/viro.2000.0276, available online at http://www.idealibrary.com onSynergistic Interactions of Antibodies in Rate of Virus Neutralization
Pietro Paolo Sanna,*,1 Fernando Ramiro-Iban˜ez,* and Alessandro De Logu*,†
*Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037; and †Sezione di Microbiologia
e Virologia, Dipartimento di Scienze Chirurgiche e Trapianti d’Organo Universita’ di Cagliari, Cagliari, Italy
Received November 29, 1999; returned to author for revision February 17, 2000; accepted February 24, 2000
Antibodies and antibody combinations are often evaluated only by their potency in inactivating a known quantity of virus
in dose–effect assays. However, a crucial additional parameter is the rate at which neutralization takes place, or kinetics.
Synergism of certain antibody combinations in dose–effect assays has been previously demonstrated. In the present report,
using a battery of murine monoclonal antibodies to herpes simplex virus (HSV), we investigated whether antiviral antibodies
can also synergize in neutralization kinetics. To determine whether synergism in dose–effect assays can predict synergism
in neutralization rate, the ability of neutralizing antibodies to synergize in neutralization rate (kinetics) was compared to their
ability to synergize in dose–effect assays (potency) in cell-free assays. Although certain antibody combinations synergized
in both neutralization rate and potency, combinations that did not clearly synergize in potency could still significantly
synergize in neutralization rate. Weak neutralizing antibodies could also greatly increase the neutralization rate of more
potent antibodies. These results suggest that evaluating antibody combinations in dose–effect assays but not in neutraliza-
tion kinetics provides a partial picture of neutralizing antibody dynamic interactions and may prevent the identification of
certain favorable antibody combinations. These findings also support the importance of establishing defined antibody
cocktails for prophylactic and therapeutic purposes. A simple strategy to evaluate antibody interactions in neutralization
kinetics is proposed in which a quantitative prediction of additivity is made on the basis of the neutralization rate constants
of the individual antibodies in the combination. © 2000 Academic PressINTRODUCTION
Advances in antibody technology have greatly in-
creased our ability to isolate human recombinant mono-
clonal antibodies and to humanize murine antibodies of
therapeutic value (Barbas and Burton, 1996; Williamson
et al., 1993). This has cleared the way for the potential
use of selected monoclonal antibodies, or cocktails of
monoclonal antibodies, in the prophylaxis and treatment
of several viral human maladies. The potential therapeu-
tic exploitation of passive immunization with human or
humanized monoclonal antibodies of defined specifici-
ties makes the study of the dynamic interactions of
antibodies of great significance, especially if implica-
tions relevant to their potential clinical use can be de-
rived.
While a general role for antibodies in the prevention of
viral infection, reinfection, and recovery from infection is
widely accepted, the exact mechanisms by which anti-
bodies confer protection in vivo remain a matter of con-
troversy. This is at least in part due to the difficulty of
teasing apart the roles of different antibody-mediated
mechanisms such as cell-free virus neutralization, lytic
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386and nonlytic mechanisms in different settings, and virus–
host systems. In addition, different antibodies to the
same virus can act through different mechanisms (see,
for instance, Eis Hubinger et al., 1991; Lefrancois, 1984;
Mester et al., 1991). However, great attention is usually
given to the ability of antibodies to neutralize cell-free
virus, and it appears reasonable that, at least in the
prophylactic setting, this is likely to be a major protective
mechanism (Moore and Burton, 1999).
Neutralization can be described in terms of potency,
efficacy, and the rate of neutralization, or kinetics. Po-
tency and efficacy are best represented by dose–effect
(or log dose–effect) curves, in which the magnitudes of
neutralization at different antibody concentrations are
plotted against the different concentrations of the anti-
body or the log10 of such concentrations, respectively.
Pharmacologically, potency refers to the location of the
dose–effect curve on the dose axis or, in other words, the
concentration required to produce a defined effect (e.g.,
50% of the maximal effect of a drug or other biological
response modifier) (Goodman Gilman et al., 1985). For
neutralizing antibodies, potency is usually defined as the
concentration required to produce 50 or 80% reduction of
infectivity. Efficacy—which is independent of potency—
can be defined as the maximal response obtained on the
y or response axis (Goodman Gilman et al., 1985). The
ability to produce a maximal response (in the case of
neutralization, total loss of infectivity) can therefore be
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387NEUTRALIZING ANTIBODY SYNERGISMdefined as 100% efficacy, while the presence of a non-
neutralized or persistent fraction despite excess of anti-
body present indicates a less than 100% efficacy.
The kinetics (or the time course) of the neutralization
reaction is described by plots in which the log10 of the
residual infectivities at predetermined time points after
the addition of a fixed concentration of antibody are
plotted against time (Dulbecco et al., 1956). This plot,
which also allows determination of the neutralization
rate constant, has been utilized for several purposes,
from serotyping of related viruses (Figueroa and Rawls,
1969; McBride, 1959), to gaining insight into the mecha-
nisms of neutralization itself (Della Porta and Westaway,
1978; Dimmock, 1993; Dulbecco et al., 1956).
In the present study, using a battery of murine mono-
clonal antibodies to herpes simplex virus (HSV), we in-
vestigated whether antiviral antibodies can synergize in
neutralization kinetics and whether synergism in dose–
effect assays can predict synergism in neutralization
kinetics. The ability of certain combinations of antibodies
to display increased neutralizing potency (Lussenhop et
al., 1988) or reduced persistent fractions and enhanced
neutralization rate has been noted before (Howard et al.,
1985; Kingsford, 1984). We have observed that certain
antibody combinations synergized both in neutralization
rate and in potency, while other combinations that did not
clearly synergize in potency could still significantly syn-
ergize in neutralization rate. Finally, weak neutralizing
antibodies could also greatly increase the neutralization
rate of more potent antibodies. Representative situations
encountered are reported. Examples of significant syn-
ergism in dose–effect neutralization assays were also
demonstrated in some recent reports (Li et al., 1997,
1998; Mascola et al., 1997; Vijh-Warrier et al., 1996).
However, the in vivo significance of neutralizing antibody
synergism remains to be elucidated.
A simple strategy for evaluating quantitatively the dy-
namic interactions of antibodies in neutralization kinetics
was devised. The neutralization rate constant observed
for the antibody combinations (Ko) was compared to the
predicted neutralization rate for additivity (Ka), and the
isobologram analysis of Chou and Talalay, (1984) was
then adapted to the neutralization rate to validate the
conclusions reached. HSV was used as a model system
of general relevance because of the large number of
specific mAbs available against this agent (Eisenberg
and Cohen, 1986; Muggeridge et al., 1990) and because
of the potential use of antibodies of exceptional protec-
tive properties in the prophylaxis and, possibly, therapy
of HSV infections (Co et al., 1991; Sanna et al., 1995,
1996). Combinations of two neutralizers displayed syn-
ergism or additivity/indifference in their rate of neutral-
ization. Interestingly, significant increases in neutraliza-
tion rate could sometimes be seen even when two neu-
tralizers that did not clearly synergize in terms of potency
in dose–effect neutralization experiments were com- tbined. Last, certain weak neutralizers could substantially
increase the neutralization rate of potent neutralizing
antibody even at concentrations well below those
needed to display significant neutralization when used
individually.
These results suggest that evaluating antibody inter-
actions by potency alone and not in neutralization kinet-
ics may prevent the identification of certain favorable
antibody combinations. This conclusion is of great rele-
vance to the design of cocktails of monoclonal antibod-
ies for the prophylaxis and therapy of viral disease in
which synergism in neutralization rate could be a major
benefit.
RESULTS
Quantitative prediction of residual infectivity using the
neutralization kinetic constant
In neutralization kinetics, the neutralization kinetic
constant relationship [Eq. (1); see Materials and Meth-
ods] allows for quantitative predictions of the residual
infectivities (V/Vo) at different antibody concentrations as
escribed in the methods. As commonly seen, the kinet-
cs obtained showed a leveling off at later time points.
hey were nevertheless interpreted as pseudo-first order
ince their initial linear segment extrapolated through
he origin (Della Porta and Westaway, 1978; McLain and
immock, 1994). The kinetics constants were calculated
or the initial linear segments (see Materials and Meth-
ds) as done by others (McLain and Dimmock, 1994).
his is demonstrated in Fig. 1 with a monoclonal anti-
ody (mAb) preparation. As expected, when the antibody
as used alone at 10 mg/ml, the same kinetic constant
was obtained as when it was used at 5 mg/ml in the
presence of 5 mg/ml normal purified mouse antibody of
the same subclass (IgG 2A) (Fig. 1). Consequently, as
outlined under Materials and Methods, using the resid-
ual infectivity data obtained at 10 mg/ml an accurate
prediction could be made of the residual infectivity ob-
tainable at 5 mg/ml and vice versa (Fig. 1). Similarly,
redictions of additivity for antibody combinations could
lso be carried out on the basis of the neutralization rate
onstants of the individual antibodies in the combination.
o this aim, the product of the predicted residual infec-
ivities of each antibody in a mixture at their concentra-
ion in the same mixture was used as a prediction of the
esidual infectivity of the mixture at additivity (see Mate-
ials and Methods and below).
ynergism of antibody combinations in both potency
nd rate of neutralization
H170 is an antibody directed to the group VII antigenic
eterminant of gD, while H128 is a mAb to the group Ib
ntigenic determinant of the same glycoprotein. The ini-ial neutralization rates of these two antibodies on HSV-1
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388 SANNA, RAMIRO-IBAN˜EZ, AND DE LOGUwere similar (Fig. 2A). While H170 is a type-common
neutralizer, its efficacy (or the maximal response ob-
tained on the Y) barely reached 50% against HSV-1 (Fig.
2C), consistent with the marked leveling off of the last
time point considered in the neutralization kinetics (Fig.
2A). Against HSV-1, a combination of 5 mg/ml of H128 and
5 mg/ml of H170 was clearly synergistic in neutralization
kinetics (Fig. 2A). The kinetics constant observed for the
combination, Ko, was significantly higher (P , 0.001) than
he predicted kinetics constant of the mixture if the two
ntibodies were additive, Ka; the Ka/Ko ratio was 0.52 6
0.03, signifying an approximate doubling of the rate of
neutralization (Fig. 2A, Table 1). In good agreement, ap-
plying the isobologram equation of Chou and Talalay
(1984) as described under Materials and Methods, a
combination index (CI) of 0.52 6 0.03 was obtained for
he neutralization rate (Fig. 2B and Table 1). In dose–
FIG. 1. Kinetics (or time course) of neutralization of HSV with two
concentrations of a monoclonal antibody (H170) at 10 and at 5 mg/ml
(the latter in the presence of an equal amount of normal purified mouse
antibody of the same subclass, IgG 2A). For neutralization kinetics, the
log10 of the residual infectivities (V/Vo) at the different time points were
plotted against time (Materials and Methods). As expected, the neu-
tralization kinetic constants calculated with Eq. (1) (Materials and
Methods) for the two antibody concentrations were the same: 1.8 3
104 6 8.9 3 103 at 10 mg/ml and 1.8x104 6 3.3 3 103 at 5mg/ml.
onsistently, using the residual infectivity data obtained at 10 mg/ml an
ccurate prediction could be made of the residual infectivity at 5 mg/ml
and vice versa. The neutralization kinetic relationship was used in this
fashion to make predictions of additivity for antibody combinations as
described in detail under Materials and Methods.ffect experiments, the antibodies also clearly syner-ized: the plot of the combination of H170 and H128 lay
o the left of both those of H128 and H170, and a CI of
.26 at the 50% neutralization end point was determined
Fig. 2D and Table 1). Finally, the combination of the two
ntibodies displayed 100% efficacy, as observed with
SV-2. This antibody combination exemplifies synergism
etween neutralizers in both neutralization rate and do-
e–effect assays.
ynergism of antibody combinations in rate of
eutralization but not in potency
H170 and H128 neutralized HSV-2 with higher neutral-
zation rates and potencies on HSV-2 than on HSV-1
Figs. 3A and 3D and Table 1). The efficacy of H170 was
ubstantially higher on HSV-2 than on HSV-1, approach-
ng 90% (Fig. 3C). As with HSV-1, a mixture containing 5
mg/ml of H128 and 5 mg/ml of H170 displayed a much
greater rate of neutralization on HSV-2 than 10 mg/ml of
each of the antibodies alone (Fig. 3A). The Ko was sig-
ificantly higher (P , 0.001) than the Ka (Table 1), as were
he differences between Ko and the kinetics constant of
ither antibody alone (both P , 0.001). The Ka/Ko ratio of
the combination was 0.56 60.04, signifying a rate of
neutralization almost double of that predicted by additiv-
ity (Table 1). A CI of 0.58 6 0.06 was obtained for this
ombination, consistent with synergism in rate of neu-
ralization. Conversely, in dose–effect neutralization ex-
eriments (Figs. 3C and 3D and Table 1), the two anti-
odies only displayed additivity at the 50% neutralization
nd point (Fig. 3D), as evaluated by the isobologram
quation of Chou and Talalay (1984). An apparent syner-
istic behavior seen at 80% neutralization could be due,
t least in part, to the neutralization of the persistent
raction of H170, an antibody with less than 100% effi-
acy, by a second antibody (Fig. 3C), a well-known effect.
hese results demonstrate that antibodies that do not
learly synergize in potency can substantially synergize
n rate of neutralization. Therefore, evaluating antibody
nteractions in dose–effect assays alone may prevent the
dentification of such potentially favorable antibody inter-
ctions.
eak neutralizing antibodies can increase the
eutralization rate of potent neutralizing antibodies
Whether weak neutralizing antibodies could synergize
ith more potent neutralizers was then addressed. For
his purpose, several antibody combinations including
Ab H170 with H222, a weak neutralizer specific for
SV-2 gE, were tested. In neutralization kinetics, the
eutralization rate of the mixture did not significantly
iffer from that of H170 alone (P 5 0.25), while H222
lone, at 10 mg/ml, produced only minimal reductions in
viral infectivity (Fig. 5A). The Ko for the mixture of H170 1
222 was significantly higher (P , 0.001) than the K ,a
and the Ka/Ko ratio was 0.61 6 0.05 (Fig. 4A, Table 1).
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389NEUTRALIZING ANTIBODY SYNERGISMConsistently, a CI of 0.66 6 0.06 was calculated for the
eutralization rate (Fig. 4B, Table 1). Therefore this anti-
ody combination was deemed synergistic in neutraliza-
FIG. 2. The combination of H170 and H128 synergized both in neutraliz
he time course) of the neutralization reaction is described by plots in wh
he addition of a fixed concentration of antibody are plotted against time. I
of H128 was clearly synergistic. The neutralization rate of the mixture was
.03. The difference between Ka and Ko was highly significant (P , 0.001)
ine, open squares). (B) When the neutralization rates observed for the com
n adaptation of the Chou and Talalay equation (see Materials and Met
ynergistic. The predicted concentration for the combination required to
(dashed line, open square), was significantly higher (P , 0.001) than th
ombination index (CI) of 0.52 6 0.03 was obtained. (C) To evaluate the
laques obtained at each antibody concentration in 1 h was plotted agains
as percentage of virus neutralized. The combination of H170 and H128 sho
and H170 alone. The combination also displayed 100% efficacy, as observe
H128 and H170 at 50% neutralization of HSV-1. Error bars in the graphs re
T
Comparison of Antibody Combinatio
mAbs
Virus
serotype
Neutralization k
K antibody
alone
K combination
observed (Ko)
K additivity
predicted (Ka)
H170
HSV-2
5.7 3 104 6 6.3 3 103
9.1 3 104 6 1.2 3 103 5.1 3 104 6 4.7 3 103
H128 4.5 3 104 6 3.7 3 103
H170
HSV-1
3.1 3 104 6 3.0 3 103
5.2 3 104 6 3.6 3 103 2.7 3 104 6 1.9 3 103
H128 2.4 3 104 6 1.3 3 103
H170
HSV-2
4.5 3 104 6 4.6 3 103
3.9 3 104 6 3.2 3 103 2.4 3 104 6 2.2 3 103
1109 2.4 3 103 6 0.9 3 103
H128
HSV-1
3.0 3 104 6 3.9 3 103
2.1 3 104 6 2.4 3 103 1.8 3 104 6 1.7 3 103
1122 4.6 3 103 6 0.6 3 103
a The 50% neutralization end point was considered to determine the
ability of the mixture to neutralize the non-neutralized or persistent fra
b This combination was interpreted as indifferent in neutralizatio
neutralization rate of the combination did not statistically differ from the
of indifference. In dose/effect neutralization the interaction of this co
significant trend toward antagonism was present.
c A meaningful end point, such as 50% neutralization, was not achiev
was not conducted.
d The combination did not statistically differ from the antibody alone at t
concentration (see text). The precise interaction could not be determined.tion rate. In dose-effect neutralization experiments (Fig.
4B), the combination was judged to be indifferent/addi-
tive, despite a nonsignificant trend toward synergism. In
te and in potency in HSV-1 neutralization. (A) As in Fig. 1, the kinetics (or
log10 of the residual infectivities (V/Vo) at predetermined time points after
lization kinetics of HSV-1, the combination of 5mg/ml of H170 and 5mg/ml
mately double of the predicted one as indicated by a Ka/Ko ratio of 0.52 6
so Table 1. A point-by-point prediction of additivity is also shown (dashed
and the antibodies alone were compared by isobologram analysis using
o the analysis of the neutralization rate, the interaction was also clearly
he same neutralization rate observed if the antibodies were additive, Da
entration of the antibodies in the mixture, D (solid line, black circle). A
of neutralization of antibodies or antibody combinations, the number of
10 of the antibody concentrations (log10 dose–effect curves) and expressed
ear synergism in potency, its profile laying to the left of both those of H128
HSV-2 (Fig. 3C). (D) Isobologram representation of the interaction of mAbs
t SE.
eutralization Kinetics and Potency
Potencya
Ka
nce Ka/Ko
Cl neut.
rate
Interaction
(Kinetics)
Cl potency
(50%)
Interaction
(Potency)
01 0.56 (60.04) 0.58 (60.06) synergistic 0.94 (60.09) additive
01 0.52 (60.03) 0.52 (60.03) synergistic
0.26 (60.03) synergistic
01 0.61 (60.05) 0.66 (60.06) synergistic N.A.c additive/indifferentd
5 0.86 (60.04) 0.86 (60.16) additive/indifferentb N.A.c indifferentb
of the interaction in potency since the 80% end point could reflect the
ther than a true increase in potency (see Figs. 2 and 3).
ics because the Ko was not significantly higher than Ka and the
ization rate of the better antibody in the mixture used alone, suggestive
ion also appeared to be of indifference, although a non-statistically
n at the highest concentration tested. Therefore isobologram analysisation ra
ich the
n neutra
approxi
; see al
bination
hods) t
obtain t
e conc
potency
t the log
wed clABLE 1
ns in N
inetics
Ko vs
differe
P , 0.0
P , 0.0
P , 0.0
P . 0.0
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neutral
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o
c
t
n
lization
nergism
390 SANNA, RAMIRO-IBAN˜EZ, AND DE LOGUfact, while a 1:1 combination of 5 mg/ml each of H170 and
H222 had a potency similar to that of 10 mg/ml of H170
used alone, the combination also did not significantly
differ from the prediction of indifference (i.e., the pre-
dicted potency of the more potent antibody in the mixture
used alone at its concentration in the mixture). An isobo-
logram evaluation of the potency could not be carried out
because mAb H222 did not reach the 50% end point (Fig.
4C). The results with this antibody combination demon-
strate that a weak neutralizer can substantially increase
the neutralization rate of a potent neutralizing antibody
even at concentrations well below those needed to dis-
play a neutralizing effect of its own. In addition, the weak
neutralizer used in this experiment, mAb H222, also
synergized in neutralization rate with mAb H128, another
potent neutralizer with a Ka/Ko 5 0.52 6 0.05 (not shown).
However, not all weak neutralizing antibodies could
increase the neutralization rate of more potent antibod-
ies. When mAb H128 was tested on HSV-1 in combina-
tion with a weak type-1-specific anti-gB neutralizing an-
tibody, H126, in neutralization kinetics experiments (Fig.
5A), the combination of the two antibodies resulted in a
Ko not significantly different from the predicted Ka (P 5
0.44, Table 1). The interaction of antibody H126 with the
potent neutralizer H170 in neutralization kinetics was
also one of indifference/additivity (not shown).
DISCUSSION
Antimicrobial combinations are desirable because of
FIG. 3. Antibodies, which do not display clear synergistic interaction
combination of 5 mg/ml of H128 and 5 mg/ml of H170 induced a more ra
f each of the antibodies alone. The observed kinetics constant for the c
onstant for additivity, Ka and a Ka/Ko ratio of 0.56 6 0.04 was obtaine
observed for the combination and the antibodies alone also suggested
the interaction of these two antibodies was mixed. They were additive
he end point if the antibodies were additive (dashed line, open squar
to achieve the end point, P 5 0.37 [as represented by the isobologra
eutralization (Do, Da, P 5 0.0108). This could be in part due to the ne
when combined with another antibody, although the fact that the neutra
dose range including the high concentrations might suggest a true syreduced likelihood of selecting resistant strains; poten-tial synergistic interactions, which may allow for reduced
dosage and lower toxicity (i.e., higher therapeutic indi-
ces); and, sometimes, expanded antimicrobial spectrum.
In the case of neutralizing antibodies, limiting the risk of
neutralization-escape mutants and exploiting favorable
pharmacodynamic interactions are reasons for the es-
tablishment of cocktails of therapeutically relevant anti-
bodies.
Dynamic interactions of antibacterial agents have
been more intensely investigated than interactions of
antiviral agents and neutralizing antibodies. With anti-
bacterial combinations, two types of assays have gained
widespread acceptance, checkerboard/isobologram
methods and time-kill methods (Krogstad and Moeller-
ing, 1987). Discordance between drug interactions inves-
tigated with the two methods are sometimes observed,
suggesting that the two kinds of assays measure differ-
ent antimicrobial properties. In fact, in bacteriology,
checkerboard/isobologram assays are usually inter-
preted as measures of the bacteriostatic activity, while
time-kill assays tend to be interpreted as tests of bacte-
ricidal activity (Krogstad and Moellering, 1987). Checker-
board/isobologram methods are based on dose–effect
experiments. Time-kill assays are time-course experi-
ments and are therefore somewhat similar to neutraliza-
tion kinetics. One substantial difference that should be
kept in mind is, however, that bacteria multiply during
these assays, unlike virus inocula being neutralized in a
cell-free medium. Checkerboard/isobologram methods
ms of potency, can substantially synergize in neutralization rate. (A) A
p of HSV-2 infectivity—or a higher neutralization rate—than 10 mg/ml
tion, Ko, was significantly higher (P , 0.001) than the predicted kinetics
also Table 1). (B) Isobologram comparison of the neutralization rates
ly synergistic interaction. (C) In dose–effect neutralization experiments
neutralization: Da, the predicted antibody concentration that achieved
not differ from Do (solid line, black circle), the concentration observed
)]. However, the antibodies displayed an apparent synergism at 80%
tion of the persistent fraction of an antibody with lower efficacy, H170,
curve of the combination lay to the left of that of H128 throughout the
. Error bars in the graphs represent SE.s in ter
pid dro
ombina
d (see
a clear
at 50%
e), did
m in (D
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391NEUTRALIZING ANTIBODY SYNERGISMnature of the dynamic interaction. Conversely, time-kill
assays are usually interpreted with arbitrary guidelines
(Krogstad and Moellering, 1987).
Using variations of isobologram type analyses, neu-
tralizing antibody combinations have been investigated
in dose-effect experiments in recently published studies
(Li et al., 1998; Mascola et al., 1997; Vijh-Warrier et al.,
1996). In these studies, increases in potency of antibody
combinations over additivity were demonstrated. The
rate of virus neutralization is instead not usually consid-
ered in evaluating neutralizing antibodies interactions,
despite its great potential importance in antibody neu-
tralization (Della Porta and Westaway, 1978; Dimmock,
1993; Dulbecco et al., 1956; McLain and Dimmock, 1994).
In fact, as discussed by Dimmock and McLain, the action
of a neutralizing antibody can be seen as “a race be-
tween the neutralization and the escape of the virus
particle by entry into a host cell” (McLain and Dimmock,
1994). Thus desirable kinetical qualities in neutralizing
antibodies are the ability to induce rapid virus inactiva-
tion (high neutralization rate constant) and the ability to
neutralize by an apparent first-order reaction (i.e., virus
inactivation proceeding linearly without an initial lag).
In the present study, the interactions of murine mono-
clonal antibodies to herpes simplex virus (HSV) in rate of
FIG. 4. A weak neutralizer can substantially increase the neutralizatio
for it to display a neutralizing effect of its own. (A) Neutralization kineti
in combination (open circle). The mixture of 5 mg/ml of H170 and 5 mg/
of 10 mg/ml of H170 alone (P 5 0.25), while 10 mg/ml of H222 alone p
onstant observed (Ko) for the mixture of H170 and H222 was significan
as 0.66 6 0.06. (B) The interaction of these two antibodies was a
sobologram format: Da was significantly higher (P 5 0.0213) than D, the
as obtained if, for the weaker of the two antibodies (H222), the c
eutralization constant obtained at a higher concentration, 50 mg/ml
nfectivity was minimal and the determination of the constant less reli
H222. mAb H222 displayed very limited potency and an efficacy of ,
sed alone at double the concentration of H170 in the mixture, but at th
f H170 used by itself at its concentration in the mixture (not shown),neutralization in comparison to their interactions in po- ctency were investigated. An unambiguous prediction of
additivity was necessary to draw meaningful conclu-
sions from the analysis of the effect of antibody combi-
nations in neutralization kinetics. In the absence of es-
tablished methods to quantify and compare antibody
interactions, it was postulated that for a mixture to be
additive the relative infectivity (V/Vo) of the mixture
hould be equal to the product of the relative infectivities
f the two antibodies used alone at the same concen-
rations at which they are present in the mixture, V1/Vo
and V2/Vo (see Materials and Methods). These can be
precisely derived using the kinetics constant relationship
[Eq. (1)], which correlates relative infectivity, time, and
antibody concentration. In this way, the predicted kinet-
ics constant of the mixture at additivity (Ka) can be math-
ematically determined, allowing for its statistical compar-
ison with the kinetics constant experimentally observed
in the actual antibody combination (Ko). Such comparison
llowed us to interpret the nature of the dynamic inter-
ctions of the combinations studied. This approach is
ractical and allows for the evaluation of antibody com-
inations in neutralization kinetics without the use of
rbitrary end points as is often done in time-kill assays in
acteriology. Similarly designed analyses could be de-
ised for multiple antibody comparisons. To validate our
f a potent neutralizing antibody at concentrations below those needed
SV-2 of mAbs H170 and of a weak neutralizer, H222, individually and
222 displayed a neutralization rate not significantly different from that
d only a marginal reduction in viral infectivity. The neutralization rate
r (P , 0.001) than the estimated additivity constant (Ka). The Ka/Ko ratio
arly synergistic when the kinetics constants were compared in an
ncentration in the combination (solid line, black circle). A similar result
t observed at the concentration used in (A) was replaced with the
square) because at the concentration used in (A), the reduction of
) Dose–effect neutralization of HSV-2 by mAbs H170, H222 and H170
1:1 combination of H170 and H222 had potency similar to that of H170
end point it also did not significantly differ from the predicted behavior
ting additivity or indifference. Error bars in the graphs represent SE.n rate o
cs on H
ml of H
roduce
tly bette
lso cle
mAb co
onstan
(black
able. (C
40%. Aonclusions, an isobologram type analysis was also
cere no
nifican
392 SANNA, RAMIRO-IBAN˜EZ, AND DE LOGUadapted to the evaluation of the neutralization rate of
antibody combinations (see Materials and Methods). A
very good agreement was found between the two ap-
proaches (Table 1).
All the antibodies tested displayed an apparent first-
order neutralization reaction. With regard to the rate of
neutralization, antibody combinations often displayed
significantly increased neutralization rates when com-
pared to predicted additivity even in the absence of clear
improvements in potency. Increases in neutralization
rates are highly desirable and should be considered
when designing antibody cocktails for clinical applica-
tions, irrespective of whether such combinations are
also synergistic in potency. In this regard, it is also
important to notice that neutralization potency, efficacy,
and rate are independent variables. For instance, anti-
body H128 had higher efficacy than antibody H170
against both HSV-1 and -2 (Figs. 2 and 3). However,
antibody H170 was more potent than H128 on HSV-2 and
was at least as potent on HSV-1 if potency is defined as
the concentration required to produce 50% of H170 max-
imal effect (half-maximal effect or EC50) (Goodman Gil-
man et al., 1985). The initial rates at which these anti-
bodies reduced viral infectivity in neutralization kinetics
were instead very similar on both HSV serotypes, despite
the fact that on type 1 H170 barely reached a 50%
efficacy in our hands (Fig. 2C). Actually, H170 consis-
tently displayed a higher (although nonsignificant) initial
rate of neutralization than H128 in the direct comparison
experiments (Figs. 2 and 3 and Table 1). Also supporting
FIG. 5. (A) The combination of H128 with a weak anti-gB type 1 neut
because Ko did not statistically differ from Ka nor from the kinetics of th
oncentration at which it was present in the mixture, 5 mg/ml (not show
1 (Table 1). (B) In dose–effect experiments, the effect of the mixture wa
combination was plotted against the concentrations of the better antibod
antibody alone although the 50 and the 80% neutralization end points w
dose–effect experiments was interpreted as indifference with a nonsigthe independence of neutralization potency and rate,increased rate of neutralization did not always correlate
with increased potency of the antibody mixture (Fig. 3
and Table 1).
Mechanisms of virus neutralization are quite diverse
and multiple factors may contribute to antibody syner-
gism. Antibodies directed against different epitopes of
the same antigen can bind synergistically (Gomez and
Retegui, 1994; Klonisch et al., 1996). Synergistic binding
of cocktails of antiviral antibodies directed to the same
virus glycoprotein has been proposed to be responsible
for increased neutralization (Li et al., 1998; Lussenhop et
al., 1988; Vijh-Warrier et al., 1996), for the neutralization
properties of cocktails of nonneutralizing antibodies
(Lussenhop et al., 1988), and for the broadening of the
spectrum of virus strains neutralized (Vijh-Warrier et al.,
1996). However, strict proportionalities between binding
affinity and either neutralization potency (Bachmann et
al., 1997; Brown et al., 1990; Dimmock, 1993) or neutral-
ization rate are often not demonstrable (Schofield et al.,
1997). Possible exceptions are viruses like HIV that ap-
pear to be neutralized primarily by preventing attachment
to host cells (Parren et al., 1998). In other cases, includ-
ing HSV, which are neutralized primarily by postattach-
ment mechanisms, epitope specificity appears to be im-
portant, given that different glycoproteins and specific
domains within them may be crucial in virus penetration
(Fuller et al., 1989; Fuller and Spear, 1985, 1987). In such
a scenario, simultaneous inhibition of two crucial deter-
minants for HSV interaction with receptor interaction
could account for the synergistic properties of a cocktail
H126, was interpreted as additive/indifferent in neutralization kinetics
potent of the two antibodies in the mixture, H128, used by itself at the
th Ka/Ko and the CI for the kinetics were not statistically different from
than the better antibody alone. (C) When the curve obtained with the
mixture (assumption of indifference), it still lay to the right of the better
t significantly different. Therefore the interaction of H126 and H128 in
t trend toward antagonism. Error bars in the graphs represent SE.ralizer,
e more
n). Bo
s worse
y in theof neutralizing antibodies. In the present study, a combi-
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393NEUTRALIZING ANTIBODY SYNERGISMnation of two type-common antibodies to glycoprotein
gD, H170 and H128, directed to two highly neutralizing
determinants involved in binding to HSV entry mediator A
(HveA) (formerly HVEM) (Nicola et al., 1998) was tested
gainst HSV-1 and -2. Consistent with the role in infec-
ivity of the epitope recognized by these antibodies, the
ocktail was synergistic in rate of neutralization against
oth serotypes. Unexpectedly, however, the same anti-
ody cocktail displayed a significantly higher potency
ver predicted additivity only against HSV-1. In the pro-
ess of HSV penetration, different glycoproteins are be-
ieved to be sequentially recruited in a scenario which
ould appear prone to produce synergistic interactions
etween neutralizing antibodies directed to epitopes on
ifferent glycoproteins participating in the infection pro-
esses. The role of gB in virus infection is well estab-
ished. Interestingly, an antibody directed to this glyco-
rotein failed to synergize with antibodies to gD, while an
ntibody to gE did. These observations suggest a com-
lex picture behind synergistic interactions of neutraliz-
ng antibodies, which defies simple interpretations. Fu-
ure studies will be needed to dissect the mechanisms
etermining the nature of the dynamic interaction in each
pecific example.
In the present study, antibody interactions in neutral-
zation kinetics and in dose-effect neutralization experi-
ents were compared. Synergism in both types of as-
ays was observed in some cases, as were examples of
iscordance between the two types of assays. Indiffer-
nce and additivity were also seen. The neutralization
inetics of antibody combinations were analyzed using
uantitative predictions of additivity based on the neu-
ralization rate constants of the individual antibodies in
he mixture. The results obtained with this method
greed with isobologram comparisons of the neutraliza-
ion rate constants carried out with an adaptation of the
ethod of Chou and Talalay. These results exemplify the
mportance of evaluating antibody combinations not only
n dose-effect assays but also in neutralization kinetics to
dentify certain favorable antibody combinations.
MATERIALS AND METHODS
ntibodies, cells, and viruses
HSV-1 (F) and HSV-2 (G) were obtained from Professor
ernard Roizman of the University of Chicago. Vero cells
ere obtained from ATCC. All the antibodies used for the
tudy were obtained from the Rumbaugh-Goodwin Insti-
ute for Cancer Research (Plantation, FL) as concen-
rated (;1 mg/ml) purified IgG. The following antibodies
ere used: H107 (Catalog No. 1103), a group VII type-
ommon to gD; H128 (Catalog No. 1110–2), a group Ib
ype-common to gD; H126, a type-common antibody to
B (Catalog No. 1122); and H222 (Catalog No. 1109), an
ntibody to gE-2 (Cohen et al., 1984; Pereira, 1982;
ereira et al., 1980; Sanchez-Pescador et al., 1992). Ad-itional antibodies from this or different sources were
ested in preliminary experiments, but only the most
epresentative antibody combinations were investigated
n detail and are presented here. Normal purified mouse
gG 2A was obtained from Jackson Laboratories (West
rove, PA).
eutralization kinetics
Neutralization kinetics were performed as follows:
000 plaque forming units (pfu)/ml of HSV-1(F) or HSV-
(G) were incubated with the indicated concentrations of
he different monoclonal antibodies or antibody combi-
ations in a total volume of 1 ml. Incubations were
arried out at 20°C because at this temperature the
nitial rate can be monitored more reliably and reproduc-
bly than at higher temperatures. Fifty-microliter aliquots
ere removed from the virus–antibody mixtures at the
ifferent time points. Antibody–antigen reactions were
erminated by immediately diluting such aliquots 100-fold
ith 5 ml of serum-free medium prechilled at 4°C. Such
-ml suspensions were then adsorbed on confluent Vero
onolayers in 100-mm plates for 1 h at 37°C with inter-
ittent rotary shaking. After removal of the inoculum, a
utrient overlay based on DMEM and containing 0.5%
garose and 2% heat-inactivated FCS (final concentra-
ions) was added to the plates. After the appearance of
laques, the plates were fixed with 10% Formalin in PBS,
insed, and stained with crystal violet (10% w/v in 70%
ethanol). The initial neutralization rate constant, K
hereby referred to simply as neutralization rate con-
tant), was calculated according to the equation
McBride, 1959)
K 5 ~D/t! z 2.3log~Vo/V!, (1)
where Vo and V are infectious virus at time 0 and time t,
espectively; and D is the reciprocal of the molar con-
entration of the antibody solution (1/C). The neutraliza-
ion rate constant was usually calculated at three time
oints (180, 360, and 600 s) since these points tend to be
ore linear (see figures). The log10 of the residual infec-
tivities (V/Vo) at the different time points were then plot-
ted against time (Dimmock, 1993; Dulbecco et al., 1956).
For kinetical analyses, all antibodies were tested at 10
mg/ml alone and 515 mg/ml in combination (additional
oncentrations of 5 mg/ml for antibodies alone, 10110
mg/ml for combinations, etc., were also tested as war-
ranted, see Results).
Dose–effect neutralization experiments
Potency and efficacy were determined as follows: se-
rial dilutions of antibodies or antibody combinations
were incubated for 1 h at 37°C with ;100 pfu of virus;
they were then adsorbed on confluent monolayers of
Vero cells in six-well plates for one more hour with
intermittent shaking; after removal of the inoculum, a
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394 SANNA, RAMIRO-IBAN˜EZ, AND DE LOGUnutrient overlay was applied to wells as described
above. Monolayers were fixed and stained as above. The
number of plaques obtained at each antibody concen-
tration was plotted against the log10 of the antibody
concentrations (log10 dose–effect curves). To compare
he interaction of antibodies in dose–effect experiments,
ilution series of each antibody alone and dilution series
f a 1:1 mixture of the two antibodies being tested were
ested, similarly to the neutralization kinetics experi-
ents.
efinitions of the interactions
Standard definitions were employed for antibody inter-
ctions. The interaction of two antibodies was defined as
dditive if their combined effect was equal to the pre-
icted sum of their individual effects, synergistic if they
roduced an effect statistically significantly greater than
he one predicted by simple additivity, antagonistic if
heir combined effect was smaller than the one predicted
y simple additivity, and indifferent if their combined
ffect was not statistically different from that of the most
otent antibody used alone at the same concentration at
hich it was present in the mixture. Indifference and
dditivity may sometimes be indistinguishable (indiffer-
nce/additivity).
nterpretation of the results and data analysis
Given that all of the antibodies in question neutralized
y an apparent first-order reaction (Dimmock, 1993; Dul-
ecco et al., 1956), the neutralization rate constants of
he antibodies and their combinations could be directly
ompared. The neutralization rate constants for all the
ntibodies and antibody combinations were calculated
ith Eq. (1). A prediction of additivity for the kinetics
xperiments was then made as follows on the basis of
heir individual neutralization rate constants. The pre-
icted residual infectivity (V/Vo) expected to be effected
by each antibody in the mixture at its concentration in the
mixture was derived from Eq. (1) knowing their neutral-
ization rate constants,
V/Vo 5 10
2~Kt/2.3D!, (2)
where D is the concentration of each antibody in the
mixture. The reciprocal of the product of the reductions
of infectivity expected to be effected by the two antibod-
ies (antibody 1 or 2) in the mixture individually at their
concentration in the same mixture (Vo/V1zVo/V2) was then
sed in Eq. (1) to predict the neutralization rate constant
Ka) of the mixture of the two antibodies if their interaction
as one of simple additivity (prediction of additivity):
Ka 5 ~D/t! z 2.3log~Vo/V1 z Vo/V2!. (3)
If the kinetics constant experimentally observed for the
combination (Ko) was statistically significantly greaterhan Ka, the combination was considered synergistic.
he ratio of Ka over Ko was also determined. A Ka/Ko ,1
as interpreted as synergistic, Ka/Ko 5 1 as additive, and
Ka/Ko .1 as antagonististic. In this fashion, it was also
ossible to make point by point V/Vo additivity predic-
tions (see figures).
The data obtained in the dose–effect experiments al-
lowed for isobologram comparisons at the 50% neutral-
ization end point, as well as the determination of the
combination index (CI) (Chou and Talalay, 1984; Elion et
al., 1954; Li et al., 1997). With this commonly used method
to evaluate the effects of drug or antibody combinations,
the concentrations of one of the two drugs tested in
multiples and fractions of the concentration needed by
the drug to achieve the chosen end point (50% neutral-
ization in the present case) are tabulated in arithmetic
scale on the x axis, the same data for the other drug are
tabulated on the y axis, while combinations of different
concentrations of the two drugs are plotted (Chou and
Talalay, 1984; Elion et al., 1954; Li et al., 1997). The
diagram connecting the experimental points that achieve
the designated end point can produce a straight line
(additivity, CI 5 1), a concave profile (synergism, CI ,1),
or a convex profile (antagonism, CI .1). The isobologram
equation of Chou and Talalay was used for this analysis
(Chou and Talalay, 1984),
CI 5 D1/Dx1 1 D2/Dx2, (4)
where Dx1 and Dx2 are the concentrations required by
the two antibodies alone to achieve the chosen end point
(50% neutralization), and D1 and D2 are the concentra-
ions of antibody 1 or 2, respectively, required to achieve
he chosen end point in combination. Interactions that
roduce CI ,1 are interpreted as synergistic, CI 5 1 as
additive, and CI .1 as antagonististic. Given that 1:1
mixtures were employed in the study (i.e., D1 5 D2, or
simply, D), the antibody concentration that would result in
additivity, Da, can be calculated as follows from Eq. (2)
roviding, by definition of additivity, that CI 5 1:
Da 5 1/~1/Dx1 1 1/Dx2!. (5)
Combinations that included antibodies that by them-
selves had lower effectiveness than 50% could not be
evaluated in this fashion.
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395NEUTRALIZING ANTIBODY SYNERGISMWhile this isobologram analysis is usually employed
for dose–effect experiments, we also adapted it to kinet-
ics data to validate the conclusions obtained by compar-
ing Ko and Ka as outlined above. To this aim, the following
modifications of Eq. (4) were introduced: Dx1 and Dx2
were the concentrations required by the two antibodies
alone to achieve the neutralization rate observed in the
combination mix and D1 and D2 were the concentrations
f antibody 1 or 2 in the combination mix and were
herefore known. Again, since 1:1 mixtures were em-
loyed, D1 5 D2 5 D. Given that the neutralization rate
onstants for each antibody had been determined, Dx1
and Dx2 could be determined from Eq. (1). Da values
ere considered to statistically differ from D if they
iffered by more than two standard deviations.
Calculations were carried out with the spreadsheet
rogram Excel (Microsoft, Seattle, WA) with specifically
esigned macros. Statistical analyses were carried out
y ANOVA followed by post hoc analyses as warranted
sing the StatView statistical package (Abacus Con-
epts, Berkley, CA). Interpolations to determine 50% neu-
ralization endpoints in dose–effect experiments were
arried out by linear regression analysis with the same
tatistical package. The data presented are compiled
rom three to five independent replications.
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